NVS - Novartis AG
| Previous close | 79.74 |
| Open | 77.54 |
| Bid | 78.95 x 800 |
| Ask | 80.00 x 1000 |
| Day's range | 77.16 - 81.04 |
| 52-week range | 69.18 - 99.84 |
| Volume | 2,654,041 |
| Avg. volume | 2,743,967 |
| Market cap | 176.716B |
| Beta (5Y monthly) | 0.54 |
| PE ratio (TTM) | 15.67 |
| EPS (TTM) | 5.06 |
| Earnings date | N/A |
| Forward dividend & yield | 3.09 (3.87%) |
| Ex-dividend date | 02 Mar 2020 |
| 1y target est | 102.67 |
- Business Wire
ROSEN, A HIGHLY RANKED FIRM, Continues to Investigate Securities Claims Against Novartis AG – NVS
Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG (NYSE: NVS) resulting from allegations that Novartis may have issued materially misleading business information to the investing public.
- Zacks
Novartis to Donate Generic Hydroxychloroquine for Coronavirus
Novartis (NVS) will donate 130 million doses of generic hydroxychloroquine for COVID-19 treatment.
- Zacks
J&J Files NDA for Multiple Sclerosis Drug Ponesimod in U.S.
Johnson & Johnson's (JNJ) ponesimod's regulatory application in U.S is based on data from the head-to-head OPTIMUM phase III study, comparing it to Sanofi's MS drug, Aubagio.
- Zacks
Aduro's (ADRO) Earnings & Revenues Miss Estimates in Q4
Aduro (ADRO) incurs wider-than-expected loss in Q4. Revenues too fall short of the mark.
- Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG.
- GlobeNewswire
ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against Novartis AG – NVS
NEW YORK, March 09, 2020 -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG.
- Zacks
J&J Files MAA for Multiple Sclerosis Drug Ponesimod in Europe
Ponesimod's regulatory application in Europe is based on data from the head-to-head OPTIMUM phase III study comparing it to Sanofi's (SNY) MS drug, Aubagio
- Zacks
Alnylam's Givlaari Gets Approval in Europe for Rare Disease
Alnylam's (ALNY) second RNAi-based therapeutics, Givlaari receives approval in Europe for treating acute hepatic porphyria, becoming the first and only approved therapy for the indication.
- Zacks
The Zacks Analyst Blog Highlights: Merck, Novartis, Mondelez International, ServiceNow and General Dynamics
The Zacks Analyst Blog Highlights: Merck, Novartis, Mondelez International, ServiceNow and General Dynamics
- Zacks
Top Analyst Reports for Merck, Novartis & Mondelez
Top Analyst Reports for Merck, Novartis & Mondelez
- Zacks
Roche's Esbriet Gets FDA Breakthrough Tag for New Indication
Roche (RHHBY) gets Breakthrough Therapy status from the FDA for Esbriet in adults with unclassifiable interstitial lung disease.
- Zacks
Pharma Stock Roundup: FDA Updates From LLY, GSK, NVS, SNY to Spin-Off API Unit
FDA accepts Glaxo (GSK) and Novartis' (NVS) sBLA. FDA gives approval to Lilly's (LLY) Trulicity for cardiovascular indication.
- Zacks
Bayer (BAYRY) Q4 Earnings Beat Estimates, Sales Rise Y/Y
Bayer (BAYRY) beats earnings estimates in the fourth quarter of 2019.
- Zacks
Pharma Stock Roundup: AZN Reports Q4 Results, NVS, PFE Drugs Get EU Approval
AstraZeneca's (AZN) Q4 results were disappointing. European Commission approves Novartis (NVS) and Pfizer's (PFE) new drugs.
- Zacks
Incyte (INCY) Q4 Earnings Top Estimates on Solid Jakafi Sales
Incyte (INCY) beats on earnings & sales in the fourth quarter on strong Jakafi growth.
- Zacks
Incyte's (INCY) Capmatinib NDA Gets Priority Review From FDA
The FDA accepts Incyte's (INCY) NDA for capmatinib and grants Priority Review.
- Zacks
Regeneron Reports Positive Eylea Data From Late-Stage Study
Regeneron (REGN) announces positive two-year results from the phase III PANORAMA study on lead ophthalmology drug, Eylea.
- Zacks
Ligand (LGND) Q4 Earnings & Revenues Top Estimates, Stock Up
Ligand (LGND) reports higher-than-expected fourth-quarter 2019 earnings and revenues.
- Zacks
Incyte (INCY) to Report Q4 Earnings: What's in the Cards?
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports fourth-quarter 2019 results.
- Zacks
Alnylam's (ALNY) Q4 Earnings Miss Estimates, Sales Beat
Alnylam (ALNY) posts a wider-than-expected loss, while revenues beat estimates marginally in the fourth quarter of 2019.
- Zacks
Regeneron's (REGN) Q4 Earnings & Sales Surpass Estimates
Regeneron (REGN) beats on Q4 earnings and sales on solid performance of ophthalmology drug, Eylea, and asthma drug, Dupixent.
- Zacks
Teva's Two Pivotal Studies on Ajovy in Japan Meet Goal
Teva (TEVA) posts positive results from two phase II/III studies on Ajovy for treating patients with chronic and episodic migraine in Japan.
- Zacks
Is a Disappointment in Store for Glaxo's (GSK) Q4 Earnings?
Glaxo's (GSK) Vaccines and Respiratory segments are likely to have driven sales in the fourth quarter.
